NASDAQ:IMRN - Immuron Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.55
▲ +0.4 (9.64%)
Get New Immuron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMRN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Immuron in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.55.

This chart shows the closing price for IMRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Immuron. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2018HC WainwrightReiterated RatingBuy$20.00High
5/29/2018HC WainwrightSet Price TargetBuy$20.00Low
3/9/2018HC WainwrightReiterated RatingBuy ➝ Buy$20.00High
2/1/2018HC WainwrightReiterated RatingBuy$15.00Medium
11/20/2017HC WainwrightSet Price TargetBuy$15.00N/A
10/18/2017HC WainwrightInitiated CoverageBuy ➝ Buy$15.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

Immuron logo
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
Read More

Today's Range

Now: $4.55
Low: $4.11
High: $5.20

50 Day Range

MA: $5.04
Low: $4.80
High: $5.61

52 Week Range

Now: $4.55
Low: $1.92
High: $28.99

Volume

1,792,737 shs

Average Volume

N/A

Market Capitalization

$25.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Immuron?

The following Wall Street analysts have issued reports on Immuron in the last twelve months:
View the latest analyst ratings for IMRN.

What is the current price target for Immuron?

0 Wall Street analysts have set twelve-month price targets for Immuron in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Immuron in the next year.
View the latest price targets for IMRN.

What is the current consensus analyst rating for Immuron?

Immuron currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMRN.

How do I contact Immuron's investor relations team?

Immuron's physical mailing address is 62 LYGON STREET LEVEL 3, CARLTON C3, 3053. The company's listed phone number is (138) 892-4854 and its investor relations email address is [email protected] The official website for Immuron is www.immuron.com.au.